University of California

Stat News reports that the University of California and publisher Elsevier are fighting over open-access journal payments.

This Week in PNAS

In PNAS this week: germline variants influence tumor immune gene expression in two dozen cancer types, phylogenetic relationships of hemipteroid insects, and more.

Three studies encompassing dozens of ancient genomes are offering a closer look at complex historical population spread in North, Central, and South America.

A federal appeals court in the US has upheld a judgment that gave the Broad Institute key CRISPR patents.

Researchers used CRISPR to engineer mice that have multiple genetic variants associated with late-onset AD to facilitate research into biomarkers and treatments.

The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.

A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.

The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.

Investigators identified ties between autism spectrum disorder and mitochondrial haplogroups in mtDNA variant data from nearly 1,000 ASD-affected families.

Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders. 

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.